Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Opinion & Analysis Gilead Sciences Inc GILD

Healthcare Biotechnology
Gilead Sciences, Inc. is a biopharmaceutical company. It is engaged in advancing medicines to prevent and treat life-threatening diseases, including human immunodeficiency virus (HIV), viral hepatitis, coronavirus disease 2019 (COVID-19) and cancer. It is focused on the discovery, development and commercialization of medicines in areas of unmet medical need. Its portfolio of marketed products... see more

Opinion & Analysis (NDAQ:GILD)

Gilead, Teva, XPhyto - Global marketing potential

Mario Hose June 16, 2020

BioNTech, Gilead, Memphasys - in the spotlight of investors overnight

Mario Hose April 24, 2020

BioNTech, Gilead, Memphasys - modern science and COVID and IVF

Mario Hose March 19, 2020

Galapagos Agrees to $3.95 Billion, 10-Year Licensing Deal Plus $1.1 Billion Investment from Gilead

Streetwise Reports July 16, 2019

With acquisition of Kite Pharma, Gilead becomes a 'major player' in CAR-T arena

The Life Sciences Report August 30, 2017

HIV vaccine clinical study results in high immune response rates in healthy subjects

The Life Sciences Report June 2, 2017

Big pharma sets its sights on NASH epidemic

The Life Sciences Report May 18, 2017

The ProMIS of an Alzheimer's cure

The Life Sciences Report May 4, 2017

ContraVir's Hep B drug could be a game changer

The Life Sciences Report February 2, 2017

Exploring solutions to healthcare's spending crisis

The Life Sciences Report October 19, 2016

From acorns mighty trees can grow: Laidlaw's Jim Molloy on budding small-cap biotechs

The Life Sciences Report March 16, 2016

Biotech Bears Spark Good Vibes For These ETFs

Benzinga.com  October 6, 2015

BTIG's Hartaj Singh's advice for biotech investors: 'hold your powder' 'til winter

Gail Dutton October 1, 2015

Keep The Quality And The Large Caps With This New ETF

Benzinga.com  September 24, 2015

CAR T-cell therapeutics: Alan Leong of BioWatch looks beyond the buzz for solid early-stage plays

Gail Dutton September 10, 2015

Buy biotech when there's blood on the street: Pontifax's Ran Nussbaum

George S. Mack September 3, 2015

The Other Bearish Biotech ETF Is Looking Groovy, Too

Benzinga.com  August 21, 2015

The Calandra Report: Darno blarno! Sales arrive for SYRX

Thom Calandra August 6, 2015

A Look Ahead: Consumer Discretionary And Greek ETFs To Watch This Week

Benzinga.com  August 2, 2015

Even With Recent Declines, Investors Still Love Biotech ETFs

Benzinga.com  July 30, 2015